The collapsed Slovenia factory project forces Porton Pharma Solutions into a first-half loss as the companies spar over alleged compliance failures and breach of contract
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
Based on the company's past public statements, Porton Pharma Solutions had high hopes for its Slovenian R&D and production base, repeatedly referring to the project as a "milestone" in its global expansion. Photo: VCG
A Novartis cross-border partnership is turning into a standoff. | A Novartis cross-border partnership is turning into a standoff.…
Eighteen months after Novo Nordisk purchased a plant in the | Eighteen months after Novo Nordisk purchased a plant in the Czech…
South Korean contract manufacturer Samsung Biologics hopes to tap into the booming peptide production and weight loss market with…
Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and…
In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals with…
Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.
